Galera Therapeutics Inc (GRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,957 | -59,082 | -62,222 | -80,534 | -74,218 |
| Depreciation Amortization | 20 | 259 | 114 | 778 | 368 |
| Income taxes - deferred | -203 | N/A | -70 | 0 | -16 |
| Accounts payable and accrued liabilities | -1,416 | -2,206 | -1,463 | -101 | 1,201 |
| Other Working Capital | -2,128 | -6,169 | 3,259 | -2,627 | 3,913 |
| Other Operating Activity | 10,539 | 22,350 | 16,956 | 14,526 | 9,215 |
| Operating Cash Flow | $-12,145 | $-44,848 | $-43,426 | $-67,958 | $-59,537 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 27,352 | 24,019 | 5,521 | 37,004 |
| PPE Investments | 4 | -59 | -25 | -283 | -457 |
| Net Acquisitions | -50 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-46 | $27,293 | $23,994 | $5,238 | $36,547 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,223 | 31,496 | 3,889 | 9,207 | 506 |
| Other Financing Activity | 0 | 0 | 0 | 57,500 | 20,000 |
| Financing Cash Flow | $2,223 | $31,496 | $3,889 | $66,707 | $20,506 |
| Beginning Cash Position | 18,257 | 4,316 | 19,859 | 15,872 | 18,356 |
| End Cash Position | 8,289 | 18,257 | 4,316 | 19,859 | 15,872 |
| Net Cash Flow | $-9,968 | $13,941 | $-15,543 | $3,987 | $-2,484 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,145 | -44,848 | -43,426 | -67,958 | -59,537 |
| Capital Expenditure | N/A | -59 | -25 | -283 | -457 |
| Free Cash Flow | -12,145 | -44,907 | -43,451 | -68,241 | -59,994 |